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the Gamma Subunit of Rod cGMP Phosphodiesterase
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Retinitis pigmentosa (RP) is the most common form of hereditary retinal degeneration, with a worldwide prevalence of 1 in 4000. Over
30 genes and loci have been implicated in nonsyndromic autosomal-recessive (ar) RP. Genome-wide homozygosity mapping was con-
ducted in two sibships from an extended consanguineous Muslim Arab Israeli family segregating ar severe early-onset RP. A shared
homozygous region on chromosome 17q25.3 was identified in both sibships, with an overlap of 4.7 Mb. One of the genes located in
this interval is PDE6G, encoding for the inhibitory g subunit of rod photoreceptor cyclic GMP-phosphodiesterase. Mutations in the
genes encoding for the catalytic subunits of this holoenzyme, PDE6A and PDE6B, cause arRP. Sequencing of all coding exons, including
exon-intron boundaries, revealed a homozygous single base change (c.187þ1G>T) located in the conserved intron 3 donor splice site of
PDE6G. This mutation cosegregated with the disease in the extended family. We used an in vitro splicing assay to demonstrate that this
mutation leads to incorrect splicing. Affected individuals had markedly constricted visual fields. Both scotopic and photopic electrore-
tinogramswere severely reduced or completely extinct. Funduscopy showed typical bone spicule-type pigment deposits spreadmainly at
the midperiphery, as well as pallor of the optic disk. Macular involvement was indicated by the lack of foveal reflex and typical cystoid
macular edema, proved by optical coherence tomography. These findings demonstrate the positive role of the g subunit in maintaining
phosphodiesterase activity and confirm the contribution of PDE6G to the etiology of RP in humans.Retinitis pigmentosa (RP, MIM 268000) is the most
common form of hereditary retinal degeneration. The
prevalence of RP in various western countries, including
Israel, is approximately 1 in 4000.1,2 RP reflects a heteroge-
neous group of retinal dystrophies characterized by night
blindness followed by visual field loss and often resulting
in severe visual impairment. Ophthalmologic findings
include characteristic pigmentation of the midperipheral
retina, attenuation of retinal arterioles, and pale appear-
ance of the optic disk.3 The disease is very heterogeneous,
both clinically and genetically, and can be inherited as
an autosomal-recessive (ar), autosomal-dominant (ad), or
X-linked trait.1 A digenic pattern of inheritance has also
been described.4 Over 40 genes and loci have been impli-
cated in nonsyndromic RP, of which over 30 are associated
with an ar mode of inheritance (Retnet: Retinal Informa-
tion Network). However, it is estimated that the genes
underlying 50% of RP cases are still unknown.
In an effort to identify previously unrecognized retinal
degeneration genes, we ascertained two nuclear Israeli
consanguineous families of Muslim Arab origin that
belong to the same extended family (family TB14, Figures
1A and 1D). In each family, the parents are first cousins.
In each of the families, there are two individuals affected
with severe early-onset RP (Figure 1A). The study was
approved by the institutional review board at Ha’Emek
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obtained from all participants or their parents.
To identify the mutated gene, we performed genome-
wide homozygosity mapping with the Infinium Human
Linkage 12 Genotyping Bead Chip (Illumina), which is
capable of genotyping 6090 highly informative SNPs
with an average genetic distance of 0.58 cM across the
human genome. The only homozygous region shared
among all four affected individuals was a 5.2 Mb interval
at the telomeric end of chromosome 17 (17q25.3),
between SNP rs10931 and the telomere (Figure 1B). SNP
analysis in both families, including nonaffected siblings
and parents, confirmed that the region segregates with
arRP (Figure 1A). A recombination event in individual
III-24 reduced the interval to 4.7 Mb between SNP
rs868432 and the telomere (Figures 1A and 1B). This
interval includes 203 genes. One of these genes is
FSCN2 (fascin homolog 2, GenBank accession number
NM_001077182), which is associated with adRP (MIM
607921, MIM 607643).5 Sequence analysis of the five
coding exons of FSCN2 was performed with the Big Dye
Terminator Cycle Sequencing Kit (PE Applied Biosystems).
No mutation was detected in affected individuals.
Another gene located within the homozygous interval
is PDE6G (GenBank accession number NM_002602,
MIM 180073), which encodes for the inhibitory subunit
of rod photoreceptor cyclic GMP-phosphodiesterase, Israel; 2Faculty of Medicine, Technion, Haifa 31096, Israel; 3Clalit, Health
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Figure 1. Genetic Analysis in Family TB14
(A) Shown are the two sibships segregating the c.187þ1G>Tmutation of PDE6G. SNP analysis performed on each of the sibships demon-
strates cosegregation of a 17q25.3-linked haplotype with arRP. Double lines indicate consanguineous unions. Filled symbols represent
affected individuals, whereas clear symbols represent unaffected individuals. Mutation-bearing haplotypes aremarked by black bars. The
position of the SNPs, based on the Human Genome Browser working draft hg18, is indicated between parentheses.
(B) Shown is chromosome 17 with the linkage intervals and the corresponding SNPs. FSCN2 and PDE6G reside within the region that is
shared by all affected individuals. Also shown is the genomic structure of PDE6G. Coding exons are represented by black boxes. Non-
coding exons are represented by white boxes. The location of the c.187þ1G>T mutation is indicated.
(C) Sequence chromatograms for the c.187þ1G>T mutation of PDE6G in a noncarrier individual (WT), an individual heterozygous for
the mutation (het), and an affected individual homozygous for the mutant allele (mut). The exon-intron boundary is marked.
(D) A pedigree of the extended family TB14. Affected individuals are marked in black. Genotypes at the c.187þ1 position are indicated.
The American Journal of Human Genetics 87, 258–264, August 13, 2010 259
Figure 2. Minigene Constructs and Products Obtained in the
In Vitro Splicing Assay
(A) Shown is a schematic representation of the constructs, which
include PDE6G exons 2 to 4 (represented by white boxes) flanked
by 82–263 bp of intronic sequences (represented by straight lines).
Vector-derived sequences are represented by a black box.
Constructs harbor either theWTor the c.187þ1G>Tmutant allele
at the donor splice site of intron 3. The locations of primers used
for RT-PCR analysis are indicated by arrows (a forward primer
located in exon 2 and a vector-derived reverse primer). Also shown
are the obtained splicing products. Sizes of exonic and intronic
fragments are indicated below them.
(B) WT and mutant (mut) constructs were transfected into Y79
cells, followed by RNA extraction and RT-PCR analysis. No PCR
products were obtained from cells transfected with the empty
pCMV-script vector (vec). b-actin (ACTB) served as an internal
control for RNA quality and quantity. M denotes size marker.(cGMP-PDE), one of the key enzymes of the visual photo-
transduction cascade in the vertebrate retina. The holoen-
zyme is a heterotetrameric complex consisting of two large
catalytic subunits, a (88 kDa) and b (84 kDa), and two iden-
tical inhibitory subunits, g (11 kDa).6 Mutations in the
genes encoding for the catalytic subunits of this holoen-
zyme, PDE6A and PDE6B, cause arRP in humans7,8 and
retinal degeneration in animal models (MIM 180071,
MIM 180072).9–12 Moreover, retinal degeneration that
resembles human RP was identified in mice lacking the
gene encoding for the g inhibitory subunit Pde6g.13 The
human PDE6G gene has been previously considered as
a candidate for RP.14,15 However, pathogenic mutations
of this gene have not been reported to date.
PDE6G harbors four exons. Sequence analysis of the
three coding exons (exons 2–4), including exon-intron
boundaries, was performed in an affected individual (indi-
vidual III-26, Figure 1A). Primer sequences are listed in
Table S1 available online. We identified a homozygous
single base change, a G-to-T transversion located in the
conserved intron 3 donor splice site (c.187þ1G>T)
(Figure 1C). This base change cosegregated with RP in
the two sibships (Figure 1A). Analysis of 25 additional
members of the extended family, including two additional
affected individuals, confirmed cosegregation of the muta-
tion with the disease. All unaffected individuals were
either heterozygotes or carried two wild-type (WT) copies.
Only the six affected individuals were homozygotes for
the identified sequence change (Figure 1D). According
to the splice-site consensus sequence in mammals, a G is
located at position þ1 of the donor site.16 To predict
the effect of c.187þ1G>T on splicing, we performed
in silico analysis of the sequence with two different
web-based tools (Splice Site Prediction by Neural Network
and MaxEntScan). Both algorithms predicted that the
c.187þ1G>T change leads to elimination of intron 3
donor site.
Because of the limited expression pattern of PDE6G, we
could not evaluate the effect of c.187þ1G>T on splicing
in patient-derived RNA. Alternatively, we used an in vitro
splicing assay approach. For this purpose, we created
a minigene construct. This construct harbors PDE6G
exons 2, 3, and 4, flanked by 82–263 bp of intronic
sequences, downstream of a cytomegalovirus (CMV) pro-
moter (Figure 2A). Two different constructs were created:
a construct harboring the WT allele (c.187þ1G) and
a construct harboring the mutant allele (c.187þ1T). Each
construct was transfected into the Y79 retinoblastoma-
derived cell line, followed by RNA extraction and RT-PCR
analysis. To analyze the results, we sequenced the splicing
products derived from each construct. RNA derived from
the WT construct yielded a main correctly spliced product
of 433 bp, which included exons 2, 3, and 4. RNA derived
from the mutant construct yielded a main aberrantly
spliced product of 461 bp. In this product, a cryptic donor
splice site, located 28 bp downstream of the mutant splice
site within intron 3, was used. Both WT and mutant260 The American Journal of Human Genetics 87, 258–264, August 1constructs also yielded an additional minor product of
392 bp, in which exon 3 was skipped (Figure 2).
To date, two PDE6G splice variants have been reported:
variant 1 (GenBank accession number NM_002602)
includes exons 1–4 and encodes for the full-length protein
of 87 amino acids, whereas variant 2 (GenBank accession
number NR_026872) is noncoding as a result of the
skipping of exon 2. To test whether alternative splicing
of exon 3 occurs in vivo, we performed RT-PCR analysis
on human retina RNA with primers derived from exons 2
and 4. Only one product was obtained, which included
exon 3 (data not shown). In addition, BLAST searches
against RNA and EST databases revealed no indication for
the existence of PDE6G transcripts lacking exon 3. We
therefore concluded that exon 3 skipping may be an arti-
fact of the in vitro splicing assay.
The in vitro splicing assay we performed demonstrates
that an intron 3 donor splice site harboring the
c.187þ1G>T change is not efficiently recognized by the
human splicing machinery. Although the exact effect of
this splicing mutation on PDE6G transcripts in human
retina is not known, the expected outcome is incorrect3, 2010
splicing, leading to an abnormal protein product. The
length of WT PDE6G protein is 87 amino acids. The use
of a cryptic intron 3 donor splice site is expected to yield
a protein of 114 amino acids, in which the last 52 amino
acids (at positions 63–114) are incorrect.
To screen control DNA samples for c.187þ1G>T, we
used a restriction-based assay. No carriers of c.187þ1G>T
were identified among 256 Muslim Israeli control subjects,
including 135 Muslim Arabs from Northern Israel, 70
Muslim Arabs from Central Israel, and 51 Bedouins.
However, c.187þ1G>T was found heterozygously in 7 of
84 random adults from the same village in which family
TB14 resides (village E), thus indicating a carrier frequency
of 8.3% (95% confidence interval, 3.6%–15.4%) in this
village. c.187þ1G>T is therefore a founder mutation of
village E and is rare in the surrounding Muslim Arab
population. Most of the Israeli Arab population has been
living in small, relatively isolated localities, which were
originally settled by a small number of founders. Most of
the genetic diseases frequent among Israeli Arabs are due
to founder effects.17 For example, we have recently identi-
fied a single founder mutation of PRCD that leads to a
high frequency of RP in another Muslim Arab Israeli
village, in which the carrier frequency is 10%.18 The iden-
tification of c.187þ1G>T as a common RP-causing muta-
tion in village E will allow for sensitive and cost-effective
use of genetic testing for carrier screening and diagnostic
purposes.
In an effort to identify additional PDE6G mutations, we
sequenced the three coding exons of 119 unrelated Israeli
patients with RP and Leber’s Congenital Amaurosis (LCA),
but no mutations were found. In addition, we analyzed
whole-genome homozygosity mapping data of 90 unre-
lated RP and LCA patients from consanguineous families.
Four of these patients had homozygous regions harboring
PDE6G, but sequencing analysis revealed no mutations.
These patients had multiple large homozygous regions,
and we predict that their disease is caused by other genes.
In total, we analyzed data from 209 RP and LCA patients,
with negative results, indicating that PDE6G mutations
are very rare and that their contribution to the overall
prevalence of RP and/or LCA in the Israeli population is
minor. Similar results were obtained by Hahn et al.,15
who screened the PDE6G gene by SSCP analysis in a total
of 704 unrelated patients with various forms of hereditary
retinal degeneration, including 471 patients with RP and
41 patients with LCA, and found no mutations.
Clinically, the affected individuals described here have
severe early-onset RP. Both scotopic and photopic electro-
retinograms (ERGs) were markedly reduced or completely
extinct by as early as 4 years of age. Visual evoked poten-
tials (VEPs) were of normal waveforms but prolonged
implicit time (data not shown). Funduscopic examination
revealed relatively mild yet typical bone spicule-type
pigment deposits in the periphery and midperiphery. In
the younger patients (aged 10 and 12), blood vessels and
optic disk were normal, whereas in their older siblingsThe Americ(aged 15 and 16), blood vessel attenuation and pallor of
the optic disk were observed. Macular involvement in all
patients was indicated by the lack of foveal reflex and cys-
toid macular edema documented by optical coherence
tomography (OCT). All patients had markedly constricted
visual fields, ranging from 10 to less than 5, with tiny
residual islands of central vision. Nevertheless, best-cor-
rected visual acuity was relatively good (Table 1; Figure 3).
These findings are similar to those reported in RP patients
due to mutations in PDE6A and PDE6B.7,8,19
As indicated before, cGMP-PDE is a key enzyme in the
visual phototransduction cascade. Vision begins when
a molecule of visual pigment, 11-cis-retinal, is photoiso-
merized by a photon of light, leading to the generation
of metarhodopsin II (R*). R* activates the G protein trans-
ducin, which in turn stimulates the activity of its effector
enzyme, cGMP-PDE. This activation is achieved by
binding of transducin to the Pg subunit, thereby removing
the inhibitory constraint from the Pa and Pb catalytic
subunits. The activated PDE lowers the intracellular
concentration of cGMP, thereby closing cGMP-gated
cation channels located on the rod plasma membrane
and initiating a neural response to light.20
As can be expected, elimination of Pa and Pb activity
results in arRP in humans and retinal degeneration in
mice.7–12 In contrast, the absence of Pgmight be expected
to reduce rod cGMP levels by allowing the constitutively
uninhibited activity of Pab. Consequently, the cGMP-
gated cation channels would be permanently closed,
eliminating the rod’s response to light. Interestingly, a
heterozygous missense mutation in Pb was identified
in a family segregating autosomal-dominant congenital
stationary night blindness (CSNB), a condition in which
rods have reduced light sensitivity but do not degenerate.
This missense mutation was eventually found to impair
the inhibitory interaction between Pb and Pg.4,21 More-
over, the p.W70A missense mutation in Pg in mice led to
rod desensitization and delayed response, a phenotype
similar to CSNB in humans.22 Surprisingly, complete elim-
ination of Pg in mice resulted in a different phenotype
that involved retinal degeneration and resembled RP in
humans. Retinal cGMP levels in Pde6g null mice were
increased, not decreased as may have been expected. The
authors hypothesized that the high cGMP concentrations
may keep cGMP-gated cation channels open continuously
and lead to an excessive energy load on rod photorecep-
tors, resulting in degeneration.13 A transgenic allele of Pg
lacking the last 7 amino acids of its C terminus did not
rescue the null phenotype.23 The conclusion was that the
interaction of Pg with Pab through its C terminus has
a positive role for the proper activation of PDE and that
all three subunits are essential for assembly of a stable,
active holoenzyme.13,23 Further support for these conclu-
sions came from biochemical and structural analyses.
These indicated that Pg domains in charge of transducin
binding (T62-I87) and Pab inhibition (N74-I87) are located
in the C terminus and are overlapping.24–26 The currentan Journal of Human Genetics 87, 258–264, August 13, 2010 261
Table 1. Clinical Characteristics of Individuals Homozygous for the PDE6G c.187þ1G>T Mutation
Patient
Number,
Sex
Age
(yrs) Eye Refractive Error
Visual
Acuitya Visual Field
Full-Field Electroretinogram
LA: Single Flashb LA: Flicker (30 Hz)c
Amp
(mV)
Latency
(mS)
Amp
(mV)
Latency
(mS)
DA:
Dim
(mV)d
DA:
Moderate
(mV)e
DA:
Bright
(mV)f
III-25, F 4 OD ND ND ND 10 44 9 27 b 0 a 17, b 12 a 27, b 45
OS ND ND ND ND ND ND ND ND ND ND
12 OD 2.25/0.75 3 170 6/12 <5 ND ND ND ND ND ND ND
OS 1.50/1.00 3 40 6/12 10 ND ND ND ND ND ND ND
III-26, M 16 OD 3.00/2.50 3 180 6/12 5 ND ND ND ND ND ND ND
OS 1.50/2.75 3 180 6/12 5 ND ND ND ND ND ND ND
III-18, M 10 OD ND 6/12þ ND 0  0  b 0 a 0, b 0 a 0, b 0
OS ND 6/12þ ND ND ND ND ND ND ND ND
15 OD 1.00/0.25 3 160 6/18 5 NA NA NA NA NA NA NA
OS 0.25/0.00 6/12 10 horizontal,
5 vertical
NA NA NA NA NA NA NA
III-19, M 7 OD ND 6/12 ND 0  0  b 0 a 0, b 0 a 0, b 0
OS ND 6/12 ND ND ND ND ND ND ND ND
10 OD þ1.75/1.25 3 180 6/18 <5 NA NA NA NA NA NA NA
OS þ1.75/2.00 3 170 6/18 <5 NA NA NA NA NA NA NA
The following abbreviations are used: F, female; M, male; OD, right eye; OS, left eye; ND, not determined; LA, light adaptation (cone ERG); DA, dark adaptation
(rod ERG); NA, not applicable.
a Best-corrected visual acuity.
b Normal amplitude (amp) is 100–300 mV; normal latency is 26–30 mS.
c Normal amplitude (amp) is 60–180 mV; normal latency is 25–30 mS.
d Normal b wave is 130–330 mV.
e Normal a wave is 150–320 mV; normal b wave is 290–500 mV.
f Normal a wave is 320–520 mV; normal b wave is 410–610 mV.hypothesis is that the interaction between activated trans-
ducin and Pg triggers a conformational change and results
in a rigid bodymovement of PgC terminus away from Pab,
whereas Pg central region could stay bound to Pab until
the binding is weakened by lowered cGMP levels.27
Based on our in vitro splicing assay, the splicing product
obtained from the c.187þ1G>T mutant allele encodes for
an abnormal Pg protein in which the last 25 amino acids
(D63-I87) are replaced by 52 irrelevant amino acids. The
missing amino acids include the overlapping regions
responsible for transducin binding and Pab inhibition.
Based on the data presented above, this mutant protein
will not enable the formation of an active PDE holoen-
zyme. This is in agreement with the observed phenotype,
which resembles the phenotype of Pde6g null mice13 and
involves severe early-onset retinal degeneration. Neverthe-
less, it is possible that different mutant alleles of PDE6G
will be discovered in the future in patients with CSNB.
Unlike the other components of rod PDE, Pg is expressed
in nonocular tissues and was found to have important
functions, including regulation of p42/p44 MAPK-depen-
dent signaling in HEK293 cells,28 prevention of phosphor-
ylation and activation of lung PDE5 by protein kinase A,29262 The American Journal of Human Genetics 87, 258–264, August 1and interaction with SH3-containing proteins.30 Based on
these findings, it could be expected that elimination of Pg
would elicit extraocular phenotypes. However, such
phenotypes were not detected in Pde6g null mice13 or in
our human RP patients.
In summary, the crucial role played by cGMP-PDE in
normal retinal function is well established. Mutations in
the catalytic a and b subunits of this holoenzyme are
a known cause of arRP. The data presented here demon-
strate the positive role of the g subunit in maintaining
PDE activity and confirm the contribution of PDE6G to
the etiology of RP in humans.Supplemental Data
Supplemental Data include one table and can be found with this
article online at http://www.cell.com/AJHG/.Acknowledgments
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